Esperion Therapeutics Inc.

NASDAQ:ESPR  
27.46
-0.22 (-0.80%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)759.23M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$41.75 Million
Adjusted EPS$0.00
See more estimates
10-Day MA$28.68
50-Day MA$29.52
200-Day MA$35.44
See more pivots

Esperion Therapeutics, Inc. Stock, NASDAQ:ESPR

3891 Ranchero Drive, Suite 150, Ann Arbor, Michigan 48108
United States of America
Phone: +1.734.887.3903
Number of Employees: 193

Description

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.